Controversial diabetes drugs actually reduce heart failure risk
GLIPTINS and glitazones do not appear to increase heart failure rates in diabetes patients, and, in fact, reduce them, a large UK study has found.
The observational study of nearly half a million patients in primary care found that, over eight years of follow-up, those prescribed a gliptin as part of dual therapy had 14% lower odds of heart failure, compared with non-users. Use of a glitazone cut risk of heart failure by 26%.
The findings follow controversy surrounding drugs from both classes. Studies have associated rosiglitazone (Avandia) with